Brought to you by 
Roche licenses Antisoma's oncology compounds
10 Dec 2002
Executive Summary
Roche licensed worldwide exclusive rights to develop, manufacture, and sell several Antisoma anticancer compounds. The five-year deal provides Roche with Phase III ovarian cancer candidate pemtumomab, Phase I compounds Therex, TheraFab, and DMXAA, and several early-stage oncology candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com